Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaufman, J. S.
Right arrow Articles by Peduzzi, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaufman, J. S.
Right arrow Articles by Peduzzi, P. N.
J Am Soc Nephrol 14:2313-2321, 2003
© 2003 American Society of Nephrology

Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis

James S. Kaufman*, Theresa Z. O’Connor{dagger}, Jane Hongyuan Zhang{dagger}, Robert E. Cronin{ddagger}, Louis D. Fiore*, Michael B. Ganz§, David S. Goldfarb|| and Peter N. Peduzzi{dagger} for the Veterans Affairs Cooperative Study Group on Hemodialysis Access Graft Thrombosis{dagger}

*Department of Veterans Affairs Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts; {dagger}Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Connecticut; {ddagger}Veterans Affairs North Texas Health Care Center, Dallas, Texas; §Cleveland Veterans Affairs Medical Center, Cleveland, Ohio; and ||New York Veterans Affairs Medical Center, New York, New York.

Correspondence to Dr. James S. Kaufman, Renal Section (111-RE), VA Boston Healthcare System, 150 S. Huntington Ave., Boston, MA 02130. Phone: 617-232-9500 (ext. 5613); Fax: 617-278-4540;

ABSTRACT. Thrombosis of hemodialysis vascular access grafts represents a major medical and economic burden. Experimental and clinical models suggest a role for antiplatelet agents in the prevention of thrombosis. The study was designed to determine the efficacy of the combination of aspirin and clopidogrel in the prevention of graft thrombosis. The study was a randomized, double-blind trial conducted at 30 hemodialysis units at Veterans Affairs medical centers. Participants undergoing hemodialysis with a polytetrafluoroethylene graft in the arm were randomized to receive either double placebos or aspirin (325 mg) and clopidogrel (75 mg) daily. Participants were to be monitored while receiving study medications for a minimum of 2 yr. The study was stopped after randomization of 200 participants, as recommended by the Data Safety and Monitoring Board because of a significantly increased risk of bleeding among the participants receiving aspirin and clopidogrel therapy. The cumulative incidence of bleeding events was significantly greater for those participants, compared with participants receiving placebos [hazard ratio, 1.98; 95% confidence interval (CI), 1.19 to 3.28; P = 0.007]. Twenty-three participants in the placebo group and 44 participants in the active treatment group experienced a bleeding event (P = 0.006). There was no significant benefit of active treatment in the prevention of thrombosis (hazard ratio, 0.81; 95% CI, 0.47 to 1.40; P = 0.45), although there was a trend toward a benefit among participants who had not experienced previous graft thrombosis (hazard ratio, 0.52; 95% CI, 0.22 to 1.26; P = 0.14). In the hemodialysis population, therapy with aspirin and clopidogrel was associated with a significantly increased risk of bleeding and probably would not result in a reduced frequency of graft thrombosis. E-mail: james.kaufman@med.va.gov




This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
S. E. ElChoufani, P. Bolin, S. Waien, C. R. Christiano, D. Holbert, and A. P. Bode
Platelet Adhesion Testing May Predict Early Hemodialysis Arteriovenous Graft and Fistula Failure in End-Stage Renal Disease Patients
Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 399 - 409.
[Abstract] [PDF]

Home page
 CJASNHome page
T. Hasegawa, S. J. Elder, J. L. Bragg-Gresham, R. L Pisoni, S. Yamazaki, T. Akizawa, M. Jadoul, R. C. Hugh, F. K Port, and S. Fukuhara
Consistent Aspirin Use Associated with Improved Arteriovenous Fistula Survival among Incident Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1373 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
R. M. Holden, G. J. Harman, M. Wang, D. Holland, and A. G. Day
Major Bleeding in Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 105 - 110.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. Khella and M. B. Bleicher
Stroke and Its Prevention in Chronic Kidney Disease
Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1343 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. H. Lee, J. E. Lee, K. W. Lee, H. Y. Nam, H. J. Jeon, Y. J. Sung, J. S. Kim, H. J. Lim, J.-s. Park, J. Y. Ko, et al.
Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2800 - 2804.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. Allon
Current Management of Vascular Access
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 786 - 800.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Roy-Chaudhury, V. P. Sukhatme, and A. K. Cheung
Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1112 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton
CHAPTER 4: Vascular Access
J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S16 - S23.
[Full Text] [PDF]

Home page
 Clin TrialsHome page
B. S Dixon, G. J Beck, L. M Dember, T. A Depner, J. J Gassman, T. Greene, J. Himmelfar, L. G Hunsicker, J. S Kaufman, J. H Lawson, et al.
Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trial
Clinical Trials, October 1, 2005; 2(5): 400 - 412.
[Abstract] [PDF]

Home page
 Clin TrialsHome page
L. M Dember, J. S Kaufman, G. J Beck, B. S Dixon, J. J Gassman, T. Greene, J. Himmelfarb, L. G Hunsicker, J. W Kusek, J. H Lawson, et al.
Design of the Dialysis Access Consortium (DAC) clopidogrel prevention of early AV fistula thrombosis trial
Clinical Trials, October 1, 2005; 2(5): 413 - 422.
[Abstract] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. J. Flanigan
Melagatran anticoagulation during haemodialysis--'Primum non nocere'
Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1789 - 1790.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. A. Knoll, P. S. Wells, D. Young, S. L. Perkins, R. M. Pilkey, J. J. Clinch, and M. A. Rodger
Thrombophilia and the Risk for Hemodialysis Vascular Access Thrombosis
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1108 - 1114.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673